Novartis | NVS - Operating Profit

Stock Price
145.47
Daily Change
-2.06 -1.40%
Monthly
-3.46%
Yearly
29.62%
Q2 Forecast
142.62

Novartis reported $4.06B in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bausch Health Companies USD 719M 2M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Canopy Growth CAD -12.66M 1.64M Dec/2025
Corcept Therapeutics USD 4.49M 5.73M Dec/2025
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
J&J USD 6.62B 1.03B Mar/2026
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Novartis USD 4.06B 521M Dec/2025
Pacira USD 3.19M 9.96M Dec/2025
Perrigo USD 84.4M 9M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 82.49M 2.82M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
Sanofi EUR 1.5B 2.29B Dec/2025
Supernus Pharmaceuticals USD 13.82M 74.01M Dec/2025
Zoetis USD 835M 101M Dec/2025